Literature DB >> 24975969

Morbidity and mortality of Iranian patients with hyper IgM syndrome: a clinical analysis.

Hassan Abolhassani1, Fatemeh Akbari, Babak Mirminachi, Saeed Bazregari, Ehsan Hedayat, Nima Rezaei, Asghar Aghamohammadi.   

Abstract

BACKGROUND: Defects in B cell class switch recombination (CSR) are a heterogeneous and yet very uncommon group of disorders which all have a genetic basis uniformly leading to hyper IgM (HIgM) syndrome. Due to the rare frequency of these conditions, a very small number of case series have been conducted on the affected patients.
OBJECTIVE: To shed some light on the morbidity and mortality regarding a relatively large cohort of diagnosed CSR defective Iranian patients.
METHODS: This study was performed using demographic information, laboratory findings and clinical data obtained from an observation of 33 Iranian patients of different ethnicities referred from all medical centers of Iran to the Children's Medical Center Hospital, pediatrics center of excellence, Tehran, Iran; of which 28 were males and 5 were females.
RESULTS: Our patients mean age at the onset of symptoms was 1.8 ± 0.2 years; they were diagnosed with a mean delay of 4.4 ± 3.3 years and followed for a mean time of 5.7 ± 4.8 years. The most prominent clinical features observed were multi-organ infections, affecting mostly the respiratory system, followed by lymphoproliferative and autoimmune disorders, the latter being of much higher frequency (44%) in our study than the reported frequency in previous reports. The three year survival rate for our enrolled patients was 67.9%.
CONCLUSIONS: Based on our findings, the most common cause of death in HIgM patients is respiratory failure. The molecular mechanism behind the nature of the CSR defective patients in Iran is more compatible with autosomal recessive mutations rather than X-linked HIgM syndrome which is in contrast with other large cohorts of patients with CSR defect.

Entities:  

Mesh:

Year:  2014        PMID: 24975969     DOI: IJIv11i2A7

Source DB:  PubMed          Journal:  Iran J Immunol        ISSN: 1735-1383            Impact factor:   1.603


  3 in total

1.  Respiratory Complications in Patients with Hyper IgM Syndrome.

Authors:  Bobak Moazzami; Reza Yazdani; Gholamreza Azizi; Fatemeh Kiaei; Mitra Tafakori; Mohammadreza Modaresi; Rohola Shirzadi; Seyed Alireza Mahdaviani; Mahsa Sohani; Hassan Abolhassani; Asghar Aghamohammadi
Journal:  J Clin Immunol       Date:  2019-06-11       Impact factor: 8.317

2.  CD40 Ligand Deficiency in Latin America: Clinical, Immunological, and Genetic Characteristics.

Authors:  Tábata Takahashi França; Lucila Akune Barreiros; Ranieri Coelho Salgado; Sarah Maria da Silva Napoleão; Lillian Nunes Gomes; Janáira Fernandes Severo Ferreira; Carolina Prando; Cristina Worm Weber; Regina Sumiko Watanabe Di Gesu; Cecilia Montenegro; Carolina Sanchez Aranda; Gisele Kuntze; Aidé Tamara Staines-Boone; Edna Venegas-Montoya; Juan Carlos Aldave Becerra; Liliana Bezrodnik; Daniela Di Giovanni; Ileana Moreira; Gisela Analia Seminario; Andrea Cecilia Gómez Raccio; Mayra de Barros Dorna; Nelson Augusto Rosário-Filho; Herberto Jose Chong-Neto; Elisa de Carvalho; Milena Baptistella Grotta; Julio Cesar Orellana; Miguel Garcia Dominguez; Oscar Porras; Laura Sasia; Karina Salvucci; Emilio Garip; Luiz Fernando Bacarini Leite; Wilma Carvalho Neves Forte; Fernanda Pinto-Mariz; Ekaterini Goudouris; María Enriqueta Nuñez Nuñez; Magdalena Schelotto; Laura Berrón Ruiz; Diana Inés Liberatore; Hans D Ochs; Otavio Cabral-Marques; Antonio Condino-Neto
Journal:  J Clin Immunol       Date:  2022-01-04       Impact factor: 8.317

3.  [Clinical and immunological profile of 15 Moroccan patients with Hyper IgM syndrome].

Authors:  Hind Ouair; Ibtihal Benhsaien; Leila Jeddane; Jalila El Bakkouri; Naima Elhafidi; Noureddine Rada; Jilali Najib; Fatima Ailal; Hanane Salih Alj; Ahmed Aziz Bousfiha
Journal:  Pan Afr Med J       Date:  2017-04-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.